Suvoda Publishes Findings From Survey on Digital Document Review and Consent
A recent survey from Suvoda about attitudes toward digital document review and consent shows that an overwhelming majority of people are comfortable reading and signing documents digitally, however, there is still reluctance when it comes to signing medical consent forms digitally.
The survey from Suvoda found that a majority of respondents (84% in the US and 73% in the UK) indicated they are comfortable signing financial, medical, education and travel documents electronically, yet just half of US respondents and 28% of UK respondents said they prefer to sign medical consent forms electronically. This preference holds up across age groups and locations of residency (urban vs. rural).
Also of note, while one-third of respondents said there is nothing that would prevent them from signing a consent form for a medical procedure or clinical trial, the main roadblocks articulated by the remaining respondents were that the forms are too confusing (46%), too long (25%), and not available in the patient’s native language (19%).
The Suvoda study was a general population Google survey of 723 US participants and 1,000 UK participants. It was conducted in the fall of 2022.
Reference
Survey From Suvoda Shows Comfort With Electronic Signatures is on the Rise, Yet Healthcare Consent Still Lags. (2023, April 19). Suvoda LLC.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
